Phenotypic screening approaches for Chagas disease drug discovery
Authors:
- 28 November 2017
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 13 (2) , 141-153
Abstract
Introduction: Chagas disease, caused by the parasite Trypanosoma cruzi, is a global public health issue. Current treatments targeting the parasite are limited to two old nitroheterocyclic drugs with serious side effects. The need for new and safer drugs has prompted numerous drug discovery efforts to identify compounds suitable for parasitological cure in the last decade. Areas covered: Target-based drug discovery has been limited by the small number of well-validated targets – the latest example being the failure of azoles, T. cruzi CYP51 inhibitors, in proof-of-concept clinical trials; instead phenotypic-based drug discovery has become the main pillar of Chagas R&D. Rather than focusing on the technical features of these screening assays, the authors describe the different assays developed and available in the field, and provide a critical view on their values and limitations in the screening cascade for Chagas drug development. Expert opinion: The application of technological advances to the field of Chagas disease has led to a variety of phenotypic assays that have not only changed the disease discovery landscape but have also helped us to gain a better understanding of parasite/host interactions. Recent examples of target resolution from phenotypic hits will uncover new opportunities for drug discovery for Chagas disease.Keywords
Funding Information
- Department for International Development (DfID), UK
- Reconstruction Credit Institution-Federal Ministry of Education and Research (KfW-BMBF), Germany
- Directorate-General for International Cooperation (DGIS), The Netherlands
- Swiss Agency for Development and Cooperation (SDC), Switzerland
- Médecins Sans Frontières (Doctors without Borders), International
This publication has 80 references indexed in Scilit:
- Mode of Death on Chagas Heart Disease: Comparison with Other Etiologies. A Subanalysis of the REMADHE Prospective TrialPLOS Neglected Tropical Diseases, 2013
- Diverse Inhibitor Chemotypes Targeting Trypanosoma cruzi CYP51PLOS Neglected Tropical Diseases, 2012
- Neglected Tropical Diseases as Hidden Causes of Cardiovascular DiseasePLOS Neglected Tropical Diseases, 2012
- High-content imaging for automated determination of host-cell infection rate by the intracellular parasite Trypanosoma cruziParasitology International, 2010
- Image-Based High-Throughput Drug Screening Targeting the Intracellular Stage of Trypanosoma cruzi , the Agent of Chagas' DiseaseAntimicrobial Agents and Chemotherapy, 2010
- In Vitro and In Vivo High-Throughput Assays for the Testing of Anti-Trypanosoma cruzi CompoundsPLOS Neglected Tropical Diseases, 2010
- Identification and Optimization of Inhibitors of Trypanosomal Cysteine Proteases: Cruzain, Rhodesain, and TbCatBJournal of Medicinal Chemistry, 2009
- Identification of Three Classes of Heteroaromatic Compounds with Activity against Intracellular Trypanosoma cruzi by Chemical Library ScreeningPLOS Neglected Tropical Diseases, 2009
- Small-Molecule Scaffolds for CYP51 Inhibitors Identified by High-Throughput Screening and Defined by X-Ray CrystallographyAntimicrobial Agents and Chemotherapy, 2007
- The Genome Sequence of Trypanosoma cruzi , Etiologic Agent of Chagas DiseaseScience, 2005